Are you busy during this broadcast? See Broadcast #2 for an alternative time.
The interaction of tumor cells and the tumor microenvironment (TME) is a highly complex, heterogeneous system, and individual for each patient. Multiple biomarkers can help improve our understanding, but current standard analysis tests are limited by the insights they can reveal. A tissue-based, multiplex immuno
In this webinar, participants will learn from three case studies using various AI-based approaches to gain insights from multi-biomarker analysis. In the first, an improved signature discovery observed with a unique biomarker combination with be discussed, followed by a panel study of seven standardized multiplexed markers that segregate non-small cell lung cancer patients into six categories and describes different immune profiles. The last study on prostate cancer shows how integrating multiplex IHC image analysis with genomic information improves patient stratification.
Ingrid Braenne, Ph.D., Team Manager Exploratory Data Science, Definiens AG
Dr. Ingrid Braenne received her Ph.D. in Bioinformatics from the University of Lübeck (Germany), where she applied machine learning approaches to group patients based on their genomic profiles. She has published over 20 papers and has many years of experience in multi-omics data analysis to identify the mechanisms underlying complex diseases. In her role as a senior scientist at the University of Virginia’s Center for Publish Health Genomics, she established pipelines to analyze longitudinal transcriptomics data using co-expression network analyses. Now as the team leader of Definiens’ exploratory data science group, she brings her expertise in machine learning and multi-omics data integration to the immuno-oncology field. Her team focuses on the identification of novel biomarkers and immune profiling using IHC and IF images, as well as on the integration of multi-omics data for a more detailed analysis of the tumor microenvironment.Message Presenter
Who Should Attend?
This webinar will be suitable for:
- Translational Scientists
- VPs of Oncology
- Directors of Immuno-Oncology programs
- Directors of Companion Diagnostics
- Directors of Profiling
- Clinical Trial Managers/Directors/VP
What You Will Learn
- The strengths of multi-biomarker analysis combined with AI
- Comprehensive immune profiling using multiplexed markers
- How to achieve better patient stratification using IHC multiplex imaging analysis and genomic information
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.